Sharon C Sung1, Stephen R Wisniewski2, James F Luther2, Madhukar H Trivedi3, A John Rush4. 1. Office of Clinical Sciences, Duke-NUS Graduate Medical School Singapore, Singapore. Electronic address: sharon.sung@duke-nus.edu.sg. 2. Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA. 3. Department of Psychiatry, The University of Texas Southwestern Medical Center, Dallas, TX, USA. 4. Office of Clinical Sciences, Duke-NUS Graduate Medical School Singapore, Singapore.
Abstract
BACKGROUND: Most patients with major depressive disorder (MDD) report clinically significant sleep problems. Pre-treatment insomnia has been associated with poorer treatment outcomes in some antidepressant trials, leading to suggestions that combined treatment regimens may be more successful in this subgroup. This study investigated this question using data from the CO-MED trial. METHODS:Adult outpatients with chronic and/or recurrent MDD were randomly assigned in 1:1:1 ratio to 28 weeks of single-blind, placebo-controlled antidepressant treatment with (1) escitalopram+placebo, (2) bupropion-sustained-release+escitalopram, or (3) venlafaxine-extended-release+mirtazapine. We compared baseline characteristics, tolerability, and treatment outcomes at 12 and 28 weeks for patients with and without pre-treatment insomnia. RESULTS: Of the 665 evaluable patients, the majority (88.3%) reported significant pre-treatment insomnia. Those with pre-treatment insomnia were more likely to be female (69.3% vs. 57.7%) and African-American (29.1% vs. 11.8%). Those with pre-treatment insomnia symptoms reported higher rates of concurrent anxiety disorders, lower rates of alcohol and substance use disorders, and greater impairment in psychosocial functioning. The two groups did not differ in either tolerability or treatment outcomes among the three antidepressant treatments. CONCLUSIONS:Insomnia symptoms, while common in patients with chronic/recurrent MDD were not predictive of response, remission, or tolerability with either single or combined antidepressant medications.
RCT Entities:
BACKGROUND: Most patients with major depressive disorder (MDD) report clinically significant sleep problems. Pre-treatment insomnia has been associated with poorer treatment outcomes in some antidepressant trials, leading to suggestions that combined treatment regimens may be more successful in this subgroup. This study investigated this question using data from the CO-MED trial. METHODS: Adult outpatients with chronic and/or recurrent MDD were randomly assigned in 1:1:1 ratio to 28 weeks of single-blind, placebo-controlled antidepressant treatment with (1) escitalopram+placebo, (2) bupropion-sustained-release+escitalopram, or (3) venlafaxine-extended-release+mirtazapine. We compared baseline characteristics, tolerability, and treatment outcomes at 12 and 28 weeks for patients with and without pre-treatment insomnia. RESULTS: Of the 665 evaluable patients, the majority (88.3%) reported significant pre-treatment insomnia. Those with pre-treatment insomnia were more likely to be female (69.3% vs. 57.7%) and African-American (29.1% vs. 11.8%). Those with pre-treatment insomnia symptoms reported higher rates of concurrent anxiety disorders, lower rates of alcohol and substance use disorders, and greater impairment in psychosocial functioning. The two groups did not differ in either tolerability or treatment outcomes among the three antidepressant treatments. CONCLUSIONS:Insomnia symptoms, while common in patients with chronic/recurrent MDD were not predictive of response, remission, or tolerability with either single or combined antidepressant medications.
Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112
Authors: Madhukar H Trivedi; Stephen R Wisniewski; David W Morris; Maurizio Fava; Jackie K Gollan; Diane Warden; Andrew A Nierenberg; Bradley N Gaynes; Mustafa M Husain; James F Luther; Sidney Zisook; A John Rush Journal: J Clin Psychiatry Date: 2011-06 Impact factor: 4.384
Authors: Madhukar H Trivedi; A John Rush; Bradley N Gaynes; Jonathan W Stewart; Stephen R Wisniewski; Diane Warden; Louise Ritz; James F Luther; Diane Stegman; Joanne Deveaugh-Geiss; Robert Howland Journal: Neuropsychopharmacology Date: 2007-04-04 Impact factor: 7.853
Authors: Wendy M Troxel; David J Kupfer; Charles F Reynolds; Ellen Frank; Michael E Thase; Jean M Miewald; Daniel J Buysse Journal: J Clin Psychiatry Date: 2011-11-29 Impact factor: 4.384
Authors: Rachel Manber; Jack D Edinger; Jenna L Gress; Melanie G San Pedro-Salcedo; Tracy F Kuo; Tasha Kalista Journal: Sleep Date: 2008-04 Impact factor: 5.849
Authors: Jianhua Shen; Sharon A Chung; Leonid Kayumov; Henry Moller; Naheed Hossain; Xuehua Wang; Prativa Deb; Frank Sun; Xin Huang; Marta Novak; Darryl Appleton; Colin M Shapiro Journal: Can J Psychiatry Date: 2006-01 Impact factor: 4.356
Authors: Manish K Jha; Ashley L Malchow; Bruce D Grannemann; A John Rush; Madhukar H Trivedi Journal: Neuropsychopharmacology Date: 2018-08-15 Impact factor: 7.853
Authors: Bharathi S Gadad; Manish K Jha; Andrew Czysz; Jennifer L Furman; Taryn L Mayes; Michael P Emslie; Madhukar H Trivedi Journal: J Affect Disord Date: 2017-07-05 Impact factor: 4.839
Authors: Joseph Mehltretter; Colleen Rollins; David Benrimoh; Robert Fratila; Kelly Perlman; Sonia Israel; Marc Miresco; Marina Wakid; Gustavo Turecki Journal: Front Artif Intell Date: 2020-01-21
Authors: Manfred Klöbl; Gregor Gryglewski; Lucas Rischka; Godber Mathis Godbersen; Jakob Unterholzner; Murray Bruce Reed; Paul Michenthaler; Thomas Vanicek; Edda Winkler-Pjrek; Andreas Hahn; Siegfried Kasper; Rupert Lanzenberger Journal: Front Comput Neurosci Date: 2020-10-06 Impact factor: 2.380
Authors: Lauren A Waterman; Bea Herbeck Belnap; Marie Anne Gebara; Yan Huang; Kaleab Z Abebe; Bruce L Rollman; Jordan F Karp Journal: Ann Clin Psychiatry Date: 2020-02 Impact factor: 1.567